In a significant stride towards combating pancreatic cancer, researchers from the University of Cincinnati Cancer Center have uncovered a new drug promising enough to potentially improve survival rates for one of the most lethal forms of the disease. The center's work zeroes in on a challenging aspect of pancreatic ductal adenocarcinoma (PDAC) - its ability to resist treatment - by focusing on a specific protein within the tumor's microenvironment.
Dr. Ahmet Kaynak, a postdoctoral fellow at the University's College of Medicine, took the lead in identifying the role of the protein that contributes to the tumor's robust defense mechanisms. According to a University of Cincinnati release, the newly developed drug, SapC-DOPG, targets this protein and has shown promise by reducing tumor size and increasing survival rates in animal models. These findings precede Kaynak's presentation at the American Association for Cancer Research’s Special Conference in Pancreatic Cancer scheduled for tomorrow in Boston.
The current approach spearheaded by Kaynak builds on the advances made by his mentor, Dr. Xiaoyang Qi, who developed an analog drug SapC-DOPS, now in Phase 2 clinical trials for lung cancer. Targeting Hsp70 within PDAC cells, SapC-DOPG displayed encouraging outcomes in preclinical trials. "We hope to transition to clinical settings and investigate whether SapC-DOPG can be used as a therapeutic agent in pancreatic cancer patients," Kaynak explained, according to UC News, echoing the optimism for the drug's potential in clinical use given the safety profile of its counterpart, SapC-DOPS.
Having been honored with the Cancer Center's Trainee Associate Membership Paper of the Year for one of his publications, Kaynak's work not only reflects his own devotion but also the collaborative efforts and support of the Hematology & Oncology Division at UC. The Pancreatic Cancer Action Network provided essential funding for this research, assisting in the quest to deliver real-world solutions to a form of cancer notoriously difficult to treat.
The implications of this research could spell a new dawn for PDAC treatment, offering patients renewed hope as the scientific community continues to make inroads into the molecular intricacies of this deadly disease. Kaynak's dedication to his work has already seen him present at the 2025 Frontiers in Cancer Immunotherapy Conference in New York, with his AACR Special Conference presentation poised to bring greater exposure to a potential game-changer in the oncological arena.
